

18. Hoang K, Tan JC, Derby G *et al.* Determinants of glomerular hypofiltration in aging humans. *Kidney Int* 2003; 64: 1417–1424
19. Fliser D, Zeier M, Nowack R, Ritz E. Renal functional reserve in healthy elderly people. *J Am Soc Nephrol* 1993; 3: 1371–1377
20. Higashi Y, Oshima T, Ozono R, Matsuura H, Kajiyama G. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. *Hypertension* 1997; 30: 252–258
21. Fuiano G, Sund S, Mazza G *et al.* Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. *Kidney Int* 2001; 59: 1052–1058
22. Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. *Circulation* 2003; 107: 1891–1895
23. Epstein M, Hollenberg NK. Age as a determinant of renal sodium conservation in normal man. *J Lab Clin Med* 1976; 87: 411–417
24. Weidmann P, de Myttenane-Bursztejn S, Maxwell M, Delima J. Effect of aging on plasma renin and aldosterone in man. *Kidney Int* 1975; 8: 325–333
25. Ohashi M, Fujio M, Nawata H. High plasma concentration of human natriuretic polypeptide in aged men. *J Clin Endocrinol Metab* 1987; 64: 81–85
26. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. *Arch Intern Med* 2003; 163: 356–360
27. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. *Am J Kidney Dis* 2001; 37: 79–83
28. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. *J Intern Med* 2004; 256: 70–78
29. Drusano GL, Muncie AL, Hoopes JM, Damron DJ, Warren JW. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. *J Am Ger Soc* 1988; 36: 437–441
30. Fliser D, Bischof I, Hanses A *et al.* Renal handling of drugs in the healthy elderly: creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. *Eur J Clin Pharmacol* 1999; 55: 205–211
31. Field TS, Gurwitz JH, Glynn RJ *et al.* The renal effects of non-steroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. *J Am Geriatr Soc* 1999; 47: 507–511

---

Nephrol Dial Transplant (2005) 20: 485–490

doi:10.1093/ndt/gfh689

## Ageing as a determinant of renal and vascular disease: role of endothelial factors

Matthias Barton

Medizinische Poliklinik, Universitätsspital, CH-8091 Zürich, Switzerland

**Keywords:** endothelium; growth; hypertension; hypertrophy; inflammation; reversibility

### Introduction

In developed countries, ageing is the most important risk factor for age and death after age 28. Age also determines the onset and development of the most prominent vascular and renal diseases, atherosclerosis and glomerulosclerosis. Increased vascular and renal

oxidative stress, and, as a consequence, abnormal activity of endothelium-derived molecules, such as nitric oxide (NO), angiotensin II and endothelin, are now recognized as important mechanisms controlling these disease processes. In this article, I will discuss current evidence for the involvement of endothelial factors in the genesis of vascular dysfunction and cardiorenal disease seen with ageing and present therapeutic approaches to actively interfere with these disease processes.

‘Aging changes can be attributed to development, genetic defects, the environment, disease, and the inborn aging process

The latter is the major risk factor for disease and death after age 28 in the developed countries’.

Denham Harman [1].

---

Correspondence and offprint requests to: Matthias Barton, MD, Medizinische Poliklinik, Universitätsspital, Rämistrasse 100, CH-8091 Zürich, Switzerland. Email: barton@usz.ch


## Ageing and development of cardiorenal diseases

The majority of deaths worldwide in the year 2020 will be due to cardiovascular causes, and a substantial proportion of this number will be due to the increase in the aged population expected in the next two decades [2,3]. Moreover, ageing will continue to be the most important determinant of disease in Western societies [1]. Ageing not only promotes the development of vascular disease and glomerulosclerosis [4], but is also associated with significant metabolic changes, resulting in age-dependent increases of the body mass index, development of insulin resistance and/or diabetes, as well as changes in lipid metabolism [5–9]. The incidence of hypertension increases in the elderly and may be related to enhanced sodium sensitivity and activation of the sympathetic nervous system (which are also characteristic features of chronic renal failure [10]), as well as abnormal responses to certain drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) [11]. Since all the changes described above may contribute to atherogenesis, one could argue that the increase in renal and vascular disease seen with ageing could be simply explained by these disturbances. However, the pathogenesis of age-dependent diseases appears to be more complex since it also involves local cellular changes in the kidney, the vasculature and circulating blood cells (reviewed in [12]).

### Cell injury precedes onset and determines progression of disease

Endothelial cells form the inner lining of arterial blood vessels and amount to ~1.5 kg, covering an area of approximately four tennis courts [13]. Under healthy conditions, endothelial cells constantly produce a number of vasoactive and trophic substances that control inflammation, vascular growth, vasomotion, platelet function, and plasmatic coagulation. Among others, these substances include prostacyclin, NO, superoxide anion ( $O_2^-$ ), angiotensin II, as well as endothelin-1 (reviewed in [13,14]). If disease—or physiological processes such as ageing or menopause—sets in, endothelial cell function deteriorates, and the finely tuned release of growth inhibitors and mitogens becomes dysbalanced (Figure 1).

In the vasculature, early lesions of the atherosclerotic plaque (fatty streaks) consisting of endothelial deposits of lipid-laden macrophages [15] can be detected in the fetal aorta, and their progression is aggravated by maternal hypercholesterolaemia [16]. This suggests that lipids play an essential role for disease onset and progression of atherosclerosis already early in life. Vascular endothelial cell injury is a key event in atherogenesis [15], indicating that under normal conditions intact endothelial cells protect from atherosclerosis. Similarly, in the kidney, damage of glomerular endothelial cells has been



**Fig. 1.** Proposed mechanisms of the vascular and renal ageing process. A continuous increase in cellular oxidative stress with ageing results in a shift promoting activity and production of vasoactive mediators. Enhanced formation of growth-promoting factors such as superoxide anion, angiotensin II and endothelin-1 counteracts the loss of anti-inflammatory and growth inhibitory mediators such as nitric oxide and prostacyclin with increasing age.

reported to contribute substantially to sclerosis of the glomerulus [12]. Consequently, endothelial factors such as endothelin-1 have been identified to play a direct role in the genesis of experimental glomerulosclerosis and atherosclerosis (reviewed in [14]), and analogies between ‘accelerated ageing’ and uraemia have been proposed [17]. Thus, it would not be surprising if changes in production and/or activity of these mediators with ageing would either promote or delay the disease process. Some of the first direct evidence for this hypothesis will be discussed below.

### Importance of the L-arginine/nitric oxide pathway

NO, a short-lived gaseous molecule, is the most important endogenous vasodilator, which also shares strong anti-aggregatory and anti-inflammatory properties [18]. NO reacts with  $O_2^-$  at a diffusion-limited rate of  $6.7 \times 10^9/s$ , thereby reducing the bioactivity of NO and resulting in formation of the cytotoxic peroxynitrite [19]. In rats, a species normally resistant to atherosclerosis but not to glomerulosclerosis, ageing is associated with a marked decrease of basal [20] as well as stimulated endothelial NO bioactivity in the systemic arterial circulation [20,21]. Impaired function of endothelium-dependent pathways has also been observed in rat coronary arterioles [24], vessels which in humans do not develop atherosclerosis even if epicardial arteries are affected. An attenuation of endothelium-dependent vasodilatation with ageing has been observed in the human brachial artery [22].

The age-associated reduction of NO bioactivity is associated with an increase in expression of the ‘inflammatory’ isoform of NO synthase, NOS2 [23,24], increased NADPH oxidase activity and formation of  $O_2^-$  [24,25]. As a consequence, vascular peroxynitrite formation increases, causing nitrosylation and functional alteration of vascular proteins [19,24]. Indirect evidence suggests that alterations of the L-arginine/NO

pathway also occur with ageing. These observations include reductions of circulating NO metabolites [26] and changes in basal NO release [20,27], as well as reduced renal NO metabolite excretion [27]. While vascular NOS2 expression increases with ageing [23,24], NOS3 isoenzyme expression appears to be regulated depending on gender [20,23]. We have shown previously that in aged Wistar rats, aortic NOS3 gene expression decreases in females [20] while an increase occurs in males [23]. This finding has been confirmed recently by Pollock's group, who found a similar regulation pattern in aged rat mesenteric arteries [28]. With intermediate ageing, tissue levels of the stable NO metabolites, nitrate/nitrite, decrease in the kidney [29]. However, with advanced ageing, changes occur in an anatomically distinct pattern, showing decreased levels of NO metabolites selectively in the renal cortex but not in the medulla [30]. This selective regulation of NO bioactivity may be related to distinct local changes of factors regulating renal NO release, such as local increases in endothelin-3 [30,31].

Other endothelial factors, such as vascular endothelial growth factor (VEGF), also appear to be involved in age-dependent changes and are regulated in an NO-dependent fashion. There is experimental evidence to suggest that the ability for tissue repair through sprouting of new vessels (angiogenesis), which requires the presence of VEGF, is impaired in aged mice [32,33]. Plasmid-mediated gene transfer of DNA encoding human *VEGF165* can increase hindlimb angiogenesis in aged animals after 40 days comparably with the degree of vascularization seen in untreated young animals. Whether the expression of VEGF and its therapeutic effects on angiogenesis can also be achieved thereafter remains uncertain. Also, given the safety concerns that arose from human VEGF gene therapy trials, it is unlikely that gene therapy represents an option to interfere successfully with vascular ageing in humans.

### Age-associated changes due to endothelial factors: truly irreversible?

Over the past centuries, scientists have developed more than 300 theories to explain the ageing phenomenon, many of which are based on the notion that age-dependent changes accumulate with time [34]. The 'free radical theory of ageing' was put forward by Denham Harman already half a century ago (reviewed in [34,35]) and is based on the chemical nature and ubiquitous presence of free radicals. Indeed, several lines of evidence now indicate that cellular oxidative stress caused by reactive oxygen species (ROS) is an important factor contributing to ageing-associated organ injury. In addition to ROS-induced DNA damage in the nucleus as well as in mitochondria, ageing of endothelial cells is associated with an 'inflammatory' phenotype as well as alterations of cell organelles, signs of cell senescence, abnormal activity of cellular mediators and/or enzymes and

vascular reactivity of vascular smooth muscle cells [23,29,36–39]. At the level of the endothelial cell, oxidative stress causes cellular damage by oxidative modification of expression and function of proteins [37–39]. Therefore, it would be desirable that any treatment aiming at interfering with or even restoring abnormal age-dependent function or structure should, at some point, inhibit the production and/or activity of ROS or enzymes involved in ROS production. There is evidence suggesting that in certain forms of disease, ROS inhibition favourably affects outcome. Indeed, blockade of endothelin receptors in experimental diabetes recently has been shown to inhibit expression of the NADPH oxidase subunit p22<sup>phox</sup>, an important source of vascular ROS [40,41], and similar data have been obtained with angiotensin AT<sub>1</sub> receptor blockers (ARBs) [42]. Thus, is it not surprising that angiotensin-converting enzyme inhibitors (ACEIs) and ARBs as well as endothelin receptor blockers are effective in preventing experimental age-related functional changes of arterial endothelial cells [43–45].

Experimental studies indicate that endothelium-dependent relaxant responses to acetylcholine are markedly reduced in the aged rat aorta, whereas the response is maintained in certain vessels such as the femoral [20] or the mesenteric artery [28]. A similar heterogeneity has been described with regard to expression of cyclooxygenase isoenzymes between ageing rat aorta and superior mesenteric artery [46]. These experimental data suggest that not only mediator activity but also transcriptional regulation of enzymes regionally differ within the ageing vasculature. If applicable for the human situation, this could at least in part explain the heterogeneity of susceptibility to atherosclerosis. Indeed, certain arteries such as the internal mammary artery and the radial artery rarely develop atherosclerosis even up to high age. Vascular activity of the antioxidant enzyme superoxide dismutase in rats is not altered by ageing [20].

In addition to the impaired NO bioactivity, which would promote vasoconstriction, there are also increases in vascular reactivity to vasoconstricting substances such as angiotensin II, endothelin-1 [29], vasoconstrictor prostanoids like prostaglandin H<sub>2</sub>/thromboxane A<sub>2</sub>, and enzyme expression of prostaglandin H synthase [46,47]. It has been shown by Remuzzi and co-workers that inhibiting the activity of angiotensin II slows the development of age-dependent glomerulosclerosis in conjunction with blood pressure lowering and a reduction of tubulointerstitial injury [49]. One of the most potent endothelial factors, endothelin-1, not only directly impairs vasomotion [48], but also controls pathological processes related to ageing. Based on our previous observation that ageing increases renal endothelin expression in the absence of hypertension [23,29], we recently have addressed the question of whether this activation might contribute to the pathogenesis of spontaneous glomerulosclerosis in the ageing kidney. Unexpectedly, we found that short-term inhibition of endothelin ET<sub>A</sub> receptors using darusentan reversed established glomerulosclerosis and proteinuria

in aged rodents, effects that were associated with partial restoration of podocyte structure [50]. Interestingly, restoration of glomeruli was associated with decreased expression of p21<sup>WAF/CIP1</sup> and matrix metalloproteinase-9, and independent of tubulo-interstitial injury, blood pressure, creatinine clearance or renal blood flow [50]. This indicates that ageing adversely affects the structure of the renal glomerulus in a locally confined and reversible manner, involving ET<sub>A</sub> receptor-mediated mechanisms that are also involved in the regulation of age-dependent changes in electrolyte excretion [51].

## Therapeutic approaches

There are several options to improve vascular function in the ageing vasculature. In addition to the experimental data using gene transfer, there are complementary approaches for 'therapeutic' angiogenesis and maintaining vascular function such as exercise training and certain cardiovascular drugs. In healthy animals, angiogenesis was increased in trained rodents as compared with sedentary animals, and the beneficial effect was abrogated by an anti-VEGF antibody [52]. A recent study in a transgenic mouse model of ageing also suggests that age-dependent reduction of angiogenesis can be effectively prevented by use of statin therapy [53]. Physical training in humans also helps to counteract the impairment of endothelium-mediated vasodilatory capacity normally seen with ageing [22,54–56], also suggested by a study comparing untrained with trained elderly men above 70 years of age [57]. Interestingly, exercise in the lower extremities may affect endothelial vasomotion in remote organs such as the arm [58], suggesting that physical exercise has systemic and possibly sustained beneficial effects.

As outlined in Figure 2, several modalities are available to interfere with age-related changes in endothelial cell function. Preventive measures, which are often already applicable for juveniles, include cessation of smoking, reduction of increased body


weight, and avoiding unbalanced diets rich in fat and sugars and low in fibres. Interestingly, nutritional additives such as vitamins appear to be largely ineffective in interfering with age-dependent functional changes. As ageing is frequently associated with a reduction of physical activity and fitness [59], it is even more important to emphasize the 'therapeutic' role of regular physical activity, which also helps to reduce the incidence and severity of related co-morbidities such as diabetes, high blood pressure, dyslipidaemia and obesity [60]. Finally, cardiovascular health awareness must be increased not only in the elderly but also in parents, including regular check-ups with their primary care physician, awareness of risk factors/ blood cholesterol levels, and blood pressure measurements. If these changes in lifestyle have been implemented and are still insufficient, medical therapy aiming at improving vascular and renal homeostasis, and reversibly restoring organ dysfunction, such as cardiac hypertrophy or proteinuria, using statins, inhibitors of the renin-angiotensin-aldosterone system (RAAS), or possibly the endothelin system can be initiated. It can be anticipated that maintaining or even improving cardiorenal health with age is not only likely to result in improved general health but can also be expected to have a positive impact on cardiovascular and renal morbidity and mortality [61–63].

**Acknowledgements.** I thank all collaborators who have contributed to our work discussed in this article and gratefully acknowledge research funding by the Swiss National Foundation (SCORE 32.58421.99 and 32-58426.99/1) and the Hanne-Liebermann-Stiftung Zürich. Presented in part at the 2nd Japanese-European Nephrology Forum, Heidelberg, Germany, June 20–23, 2002.

**Conflict of interest statement.** None declared.

## References

1. Harman D. Extending functional life span. *Exp Gerontol* 1998; 22: 95–112
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001; 104: 2746–2653
3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation* 2001; 104: 2855–2864
4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003; 41: 1–12
5. Barbieri M, Rizzo MR, Manzella D, Paolisso G. Age-related insulin resistance: is it an obligatory finding? The lesson from healthy centenarians. *Diabetes Metab Res Rev* 2001; 17: 19–26
6. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. *Med Hypotheses* 2001; 56: 702–708
7. Chvojikova S, Kazdova L, Divisova J. Age-related changes in fatty acid composition in muscles. *Tohoku J Exp Med* 2001; 195: 115–123



**Fig. 2.** The ageing endothelium: therapeutic options. Modalities to improve/reduce oxidative injury to the vascular wall and vascular endothelial cells in young as well as in elderly individuals. T2D = type 2 diabetes; C/U = medical check-up; BP = blood pressure; Rx = prescription; ACEI = angiotensin converting-enzyme inhibitor; ARB = angiotensin AT<sub>1</sub> receptor blocker



8. Zeeh J, Platt D. The aging liver: structural and functional changes and their consequences for drug treatment in old age. *Gerontology* 2002; 48: 121–127
9. Wilson PW, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. *Am J Geriatr Cardiol* 2002; 11: 119–23,125.
10. Orth SR, Amann K, Strojek K, Ritz E. Sympathetic overactivity and arterial hypertension in renal failure. *Nephrol Dial Transplant* 2001; 16: 67–69
11. Mulkerrin EC, Clark BA, Epstein FH. Increased salt retention and hypertension from non-steroidal agents in the elderly. *Q J Med* 1997; 90: 411–415
12. Brenner RM, Wrona EM. The epidemic of cardiovascular disease in end-stage renal disease. *Curr Opin Nephrol Hypertens* 1999; 8: 365–369
13. Luscher TF, Barton M. Biology of the endothelium. *Clin Cardiol* 1997; 20: II-3–10
14. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. *Circulation* 2000; 102: 2434–2440
15. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. *Science* 1973; 180: 1332–1339
16. Napoli C, D'Armiento FP, Mancini FP *et al.* Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. *J Clin Invest* 1997; 100: 2680–2690
17. Amann K, Ritz E. Cardiovascular abnormalities in ageing and in uraemia—only analogy or shared pathomechanisms? *Nephrol Dial Transplant* 1998; 13: 6–11
18. Ignarro LJ. Physiology and pathophysiology of nitric oxide. *Kidney Int Suppl* 1996; 55: S2–S5
19. Hanafy KA, Krumenacker JS, Murad F. NO, nitrotyrosine, and cyclic GMP in signal transduction. *Med Sci Monit* 2001; 7: 801–819
20. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Luscher TF. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. *Hypertension* 1997; 30: 817–824
21. Tschudi MR, Barton M, Bersinger NA *et al.* Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. *J Clin Invest* 1996; 98: 899–905
22. Taddei S, Virdis A, Ghiadoni L *et al.* Age-related reduction of NO availability and oxidative stress in humans. *Hypertension* 2001; 38: 274–279
23. Goettisch W, Lattmann T, Amann K *et al.* Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries *in vivo*: implications for atherosclerosis. *Biochem Biophys Res Commun* 2001; 280: 908–913
24. Csizsar A, Ungvari Z, Edwards JG *et al.* Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. *Circ Res* 2002; 90: 1159–1166
25. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. *Hypertension* 2001; 37: 529–534
26. Reckelhoff JF, Kellum JA, Blanchard EJ, Bacon EE, Wesley AJ, Kruckeberg WC. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. *Life Sci* 1994; 55: 1895–1902
27. Hill C, Lateef AM, Engels K, Samsell L, Baylis C. Basal and stimulated nitric oxide in control of kidney function in the aging rat. *Am J Physiol* 1997; 272: R1747–R1753
28. Sullivan JC, Dabbs Lomis E, Collins M, Imig JD, Inscho EW, Pollock JS. Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. *J Appl Physiol* 2004; 97: 1268–1274
29. Barton M, Lattmann T, d'Uscio L, Luscher T, Shaw S. Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease. *J Cardiovasc Pharmacol* 2000; 36: S153–S156
30. Lattmann T, Shaw S, Munter K, Vetter W, Barton M. Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging. *Biochem Biophys Res Commun* 2005; 327: 234–241
31. Hirata Y, Emori T, Eguchi S *et al.* Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. *J Clin Invest* 1993; 91: 1367–1373
32. Rivard A, Fabre JE, Silver M *et al.* Age-dependent impairment of angiogenesis. *Circulation* 1999; 99: 111–120
33. Rivard A, Berthou-Soulie L, Principe N *et al.* Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. *J Biol Chem* 2000; 275: 29643–29647
34. Ashok BT, Ali R. The aging paradox: free radical theory of aging. *Exp Gerontol* 1999; 34: 293–303
35. Harman D. The free radical theory of aging. *Antioxid Redox Signal* 2003; 5: 557–561
36. Haudenschild CC, Prescott MF, Chobanian AV. Aortic endothelial and subendothelial cells in experimental hypertension and aging. *Hypertension* 1981; 3: 1148–1153
37. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. *Circulation* 2002; 105: 1541–1544
38. Aviv H, Khan MY, Skurnick J *et al.* Age dependent aneuploidy and telomere length of the human vascular endothelium. *Atherosclerosis* 2001; 159: 281–287
39. Droge W. Free radicals in the physiological control of cell function. *Physiol Rev* 2002; 82: 47–95
40. Griendling KK, Harrison DG. Dual role of reactive oxygen species in vascular growth. *Circ Res* 1999; 85: 562–563
41. Griendling KK, Harrison DG. Out, damned dot: studies of the NADPH oxidase in atherosclerosis. *J Clin Invest* 2001; 108: 1423–1424
42. Rajagopalan S, Kurz S, Munzel T *et al.* Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest* 1996; 97: 1916–1923
43. Kansui Y, Fujii K, Goto K, Abe I, Iida M. Angiotensin II receptor antagonist improves age-related endothelial dysfunction. *J Hypertens* 2002; 20: 439–446
44. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction. *Hypertension* 2000; 36: 581–587
45. Kanie N, Kamata K. Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat. *Br J Pharmacol* 2002; 135: 1935–1942
46. Heymes C, Habib A, Yang D *et al.* Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. *Br J Pharmacol* 2000; 131: 804–810
47. Stewart KG, Zhang Y, Davidge ST. Aging increases PGHS-2-dependent vasoconstriction in rat mesenteric arteries. *Hypertension* 2000; 35: 1242–1247
48. Amiri F, Virdis A, Neves MF *et al.* Endothelium-dependent overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. *Circulation* 2004; 110: 2233–2240
49. Zoja C, Remuzzi A, Corna D, Perico N, Bertani T, Remuzzi G. Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. *Am J Med* 1992; 92: 60S–63S
50. Ortmann J, Amann K, Brandes RP *et al.* Role of podocytes for the reversal of glomerulosclerosis and proteinuria in the

- aging kidney after endothelin inhibition. *Hypertension* 2004; 44: 974–981
51. Traupe T, Muentner K, Barton M. Impaired sodium and potassium excretion with aging is regulated by increased endothelin. *Circulation* 2002; 106 [Suppl II]: 684
  52. Amaral SL, Papanek PE, Greene AS. Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training. *Am J Physiol* 2001; 281: H1163–H1169
  53. Shimada T, Takeshita Y, Murohara T *et al.* Angiogenesis and vasculogenesis are impaired in the precocious-aging *klotho* mouse. *Circulation* 2004; 110: 1148–1155
  54. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. *J Clin Invest* 1993; 92: 652–662
  55. Taddei S, Virdis A, Mattei P *et al.* Hypertension causes premature aging of endothelial function in humans. *Hypertension* 1997; 29: 736–743
  56. Singh N, Prasad S, Singer DR, MacAllister RJ. Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. *Clin Sci (Lond)* 2002; 102: 595–600
  57. Jensen-Urstad K, Bouvier F, Jensen-Urstad M. Preserved vascular reactivity in elderly male athletes. *Scand J Med Sci Sports* 1999; 9: 88–91
  58. Green D, Cheetham C, Mavaddat L *et al.* Effect of lower limb exercise on forearm vascular function: contribution of nitric oxide. *Am J Physiol* 2002; 283: H899–H907
  59. Mazzeo RS, Tanaka H. Exercise prescription for the elderly: current recommendations. *Sports Med* 2001; 31: 809–818
  60. Barton M, Furrer J. Cardiovascular consequences of the obesity pandemic: need for action. *Exp Opin Invest Drugs* 2003; 12: 1757–1759
  61. Jarvisalo MJ, Harmoinen A, Hakanen M *et al.* Elevated serum C-reactive protein levels and early arterial changes in healthy children. *Arterioscler Thromb Vasc Biol* 2002; 22: 1323–1328
  62. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation* 2000; 101: 1899–1906
  63. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation* 2000; 101: 948–954

Nephrol Dial Transplant (2005) 20: 490–496

doi:10.1093/ndt/gfh709

## Why patients with progressing kidney disease are referred late to the nephrologist: on causes and proposals for improvement

Jean-Pierre Wauters<sup>1</sup>, Norbert Lameire<sup>2</sup>, Alex Davison<sup>3</sup> and Eberhard Ritz<sup>4</sup>

Divisions of Nephrology of the University Hospitals – <sup>1</sup>Bern, Switzerland, <sup>2</sup>Gent, Belgium,

<sup>3</sup>Leeds, UK and <sup>4</sup>Heidelberg, Germany

**Keywords:** chronic kidney disease; dialysis; end-stage renal failure; improvement of patient care; late referral

The adverse effects arising from late referral (LR) have been reported by nephrologists over the past 20 years from several countries [1–10]: not only does LR delay the introduction of measures to attenuate the

progressive loss of kidney function and prevent uraemic complications [11], but LR has also numerous short and long-term deleterious effects on clinical outcome [1–8]. The only study that did not confirm the long-term harmful effects of LR is the study of Roubicek *et al.* [12]. It appears, however, that their definition of LR was longer (4 months before dialysis), patients were younger, with less co-morbidities and relatively long hospitalization times in both patient groups, and a shorter mean survival time of the early referral group than in most other patient series.

While a recent review analyzed the relationships between LR, mortality and morbidity, and the potential positive effects of early referral [10], the present editorial comment identifies and analyzes the different causes responsible for LR and suggests some

Correspondence and offprint requests to: J.-P. Wauters, Division of Nephrology, University Hospital, 3010 Bern, Switzerland.  
Email: jean-pierre.wauters@insel.ch